Small bowel adenocarcinoma in Crohn's disease: a systematic review and meta-analysis of the prevalence, manifestation, histopathology, and outcomes.
Crohn’s disease
Epidemiology
Small bowel adenocarcinoma
Small bowel cancers
Surgery
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
accepted:
12
10
2021
pubmed:
28
10
2021
medline:
19
1
2022
entrez:
27
10
2021
Statut:
ppublish
Résumé
Small bowel adenocarcinoma (SBA) is a rare neoplasm that is associated with Crohn's disease (CD). This study aims to quantify the prevalence of CD-SBA, review the current evidence of histopathology and molecular analysis findings, and identify the clinical presentation and outcomes of CD-SBA. Electronic databases Medline and Embase were searched for articles describing SBA in inflammatory bowel disease patients. The histopathology, molecular analysis findings, clinical presentation, prevalence, and outcomes of CD-SBA were extracted, and results were pooled with random effects. In total, 33 articles were included in the analysis. Prevalence of SBA was 1.15 (CI: 0.31-2.33) per 1000 CD patients. Only 11% (CI: 0.04-0.21) of CD-SBA patients had observable radiological features. CD-SBA was most commonly found in the ileum (84%), diagnosed at stage 2 (36%), with main presenting complaints including obstruction, weight loss, and abdominal pain. Significant histopathological findings included adjacent epithelial dysplasia, and an equal distribution of well-differentiated (49%) and poorly differentiated subtypes (46%). Most prevalent genetic mutation was KRAS mutation (18%), followed by mismatch repair deficiency (9.7%). The 5-year overall survival for CD-SBA patients was 29% (CI: 0.18-0.41), and 33% (CI: 0.26-0.41) for de novo SBA. No statistically significant increase in risk for CD-SBA was noted for treatment with thiopurines, steroids, and 5-ASA. Our meta-analysis found the prevalence of CD-SBA to be 1.15 per 1000 CD patients. The 5-year overall survival for CD-SBA was poor. The presenting symptoms were non-specific, and therefore the diagnosis requires a high index of suspicion.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Small bowel adenocarcinoma (SBA) is a rare neoplasm that is associated with Crohn's disease (CD). This study aims to quantify the prevalence of CD-SBA, review the current evidence of histopathology and molecular analysis findings, and identify the clinical presentation and outcomes of CD-SBA.
METHODS
METHODS
Electronic databases Medline and Embase were searched for articles describing SBA in inflammatory bowel disease patients. The histopathology, molecular analysis findings, clinical presentation, prevalence, and outcomes of CD-SBA were extracted, and results were pooled with random effects.
RESULTS
RESULTS
In total, 33 articles were included in the analysis. Prevalence of SBA was 1.15 (CI: 0.31-2.33) per 1000 CD patients. Only 11% (CI: 0.04-0.21) of CD-SBA patients had observable radiological features. CD-SBA was most commonly found in the ileum (84%), diagnosed at stage 2 (36%), with main presenting complaints including obstruction, weight loss, and abdominal pain. Significant histopathological findings included adjacent epithelial dysplasia, and an equal distribution of well-differentiated (49%) and poorly differentiated subtypes (46%). Most prevalent genetic mutation was KRAS mutation (18%), followed by mismatch repair deficiency (9.7%). The 5-year overall survival for CD-SBA patients was 29% (CI: 0.18-0.41), and 33% (CI: 0.26-0.41) for de novo SBA. No statistically significant increase in risk for CD-SBA was noted for treatment with thiopurines, steroids, and 5-ASA.
CONCLUSION
CONCLUSIONS
Our meta-analysis found the prevalence of CD-SBA to be 1.15 per 1000 CD patients. The 5-year overall survival for CD-SBA was poor. The presenting symptoms were non-specific, and therefore the diagnosis requires a high index of suspicion.
Identifiants
pubmed: 34704127
doi: 10.1007/s00384-021-04050-1
pii: 10.1007/s00384-021-04050-1
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
239-250Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
(2020) SEER*Explorer: an interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute (NCI), United States
Barsouk A, Rawla P, Barsouk A, Thandra KC (2019) Epidemiology of cancers of the small intestine: trends, risk factors, and prevention. Med Sci (Basel) 2019:7. https://doi.org/10.3390/medsci7030046
doi: 10.3390/medsci7030046
Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS (2009) Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 249:63–71. https://doi.org/10.1097/SLA.0b013e31818e4641
doi: 10.1097/SLA.0b013e31818e4641
pubmed: 19106677
Axelrad JE, Olen O, Sachs MC, Erichsen R, Pedersen L, Halfvarson J et al (2021) Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden. Gut 70:297–308. https://doi.org/10.1136/gutjnl-2020-320945
doi: 10.1136/gutjnl-2020-320945
pubmed: 32474410
Jess T, Loftus EV Jr, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC et al (2006) Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County. Minnesota Gastroenterology 130:1039–1046. https://doi.org/10.1053/j.gastro.2005.12.037
doi: 10.1053/j.gastro.2005.12.037
pubmed: 16618397
Jess T, Winther KV, Munkholm P, Langholz E, Binder V (2004) Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County. Denmark Aliment Pharmacol Ther 19:287–293. https://doi.org/10.1111/j.1365-2036.2004.01858.x
doi: 10.1111/j.1365-2036.2004.01858.x
pubmed: 14984375
von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP (2007) The risk of cancer in patients with Crohn’s disease. Dis Colon Rectum 50:839–855. https://doi.org/10.1007/s10350-006-0848-z
doi: 10.1007/s10350-006-0848-z
Solem CA, Harmsen WS, Zinsmeister AR, Loftus EV Jr (2004) Small intestinal adenocarcinoma in Crohn’s disease: a case-control study. Inflamm Bowel Dis 10:32–35. https://doi.org/10.1097/00054725-200401000-00005
doi: 10.1097/00054725-200401000-00005
pubmed: 15058524
Ribeiro MB, Greenstein AJ, Heimann TM, Yamazaki Y, Aufses AH Jr (1991) Adenocarcinoma of the small intestine in Crohn’s disease. Surg Gynecol Obstet 173: 343–9
Annese V (2020) Small bowel adenocarcinoma in Crohn’s disease: an underestimated risk? J Crohns Colitis 14:285–286. https://doi.org/10.1093/ecco-jcc/jjz168
doi: 10.1093/ecco-jcc/jjz168
pubmed: 32167150
Svrcek M, Piton G, Cosnes J, Beaugerie L, Vermeire S, Geboes K et al (2014) Small bowel adenocarcinomas complicating Crohn’s disease are associated with dysplasia: a pathological and molecular study. Inflamm Bowel Dis 20:1584–1592. https://doi.org/10.1097/MIB.0000000000000112
doi: 10.1097/MIB.0000000000000112
pubmed: 25029614
Aparicio T, Zaanan A, Svrcek M, Laurent-Puig P, Carrere N, Manfredi S et al (2014) Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis 46:97–104. https://doi.org/10.1016/j.dld.2013.04.013
doi: 10.1016/j.dld.2013.04.013
pubmed: 23796552
Diosdado B, Buffart TE, Watkins R, Carvalho B, Ylstra B, Tijssen M et al (2010) High-resolution array comparative genomic hybridization in sporadic and celiac disease-related small bowel adenocarcinomas. Clin Cancer Res 16:1391–1401. https://doi.org/10.1158/1078-0432.CCR-09-1773
doi: 10.1158/1078-0432.CCR-09-1773
pubmed: 20179237
Piton G, Cosnes J, Monnet E, Beaugerie L, Seksik P, Savoye G et al (2008) Risk factors associated with small bowel adenocarcinoma in Crohn’s disease: a case-control study. Am J Gastroenterol 103:1730–1736. https://doi.org/10.1111/j.1572-0241.2008.01847.x
doi: 10.1111/j.1572-0241.2008.01847.x
pubmed: 18564124
Cahill C, Gordon PH, Petrucci A, Boutros M (2014) Small bowel adenocarcinoma and Crohn’s disease: any further ahead than 50 years ago? World J Gastroenterol 20:11486–11495. https://doi.org/10.3748/wjg.v20.i33.11486
doi: 10.3748/wjg.v20.i33.11486
pubmed: 25206256
pmcid: 4155342
Hoffman JP, Taft DA, Wheelis RF, Walker JH (1977) Adenocarcinoma in regional enteritis of the small intestine. Arch Surg 112:606–611. https://doi.org/10.1001/archsurg.1977.01370050066011
doi: 10.1001/archsurg.1977.01370050066011
pubmed: 856102
Dossett LA, White LM, Welch DC, Herline AJ, Muldoon RL, Schwartz DA et al (2007) Small bowel adenocarcinoma complicating Crohn’s disease: case series and review of the literature. Am Surg 73:1181–7
Floch HF, Slattery LR, Hazzi CG (1978) Carcinoma of the small intestine in regional enteritis: presentation of a case and review of the literature. Am J Gastroenterol 70:520–7
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 6
Schwarzer G, Chemaitelly H, Abu-Raddad LJ, Rucker G (2019) Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods 10:476–483. https://doi.org/10.1002/jrsm.1348
doi: 10.1002/jrsm.1348
pubmed: 30945438
pmcid: 6767151
Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404–413. https://doi.org/10.2307/2331986
doi: 10.2307/2331986
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 2003(327):557–560. https://doi.org/10.1136/bmj.327.7414.557
doi: 10.1136/bmj.327.7414.557
Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ (2014) In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. J Clin Epidemiol 67:897–903. https://doi.org/10.1016/j.jclinepi.2014.03.003
doi: 10.1016/j.jclinepi.2014.03.003
pubmed: 24794697
Frolkis AD, Dykeman J, Negron ME, Debruyn J, Jette N, Fiest KM et al (2013) Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 145:996–1006. https://doi.org/10.1053/j.gastro.2013.07.041
doi: 10.1053/j.gastro.2013.07.041
pubmed: 23896172
Katz D, Baptista J, Azen SP, Pike MC (1978) Obtaining confidence intervals for the risk ratio in cohort studies. Biometrics 34:469–474. https://doi.org/10.2307/2530610
doi: 10.2307/2530610
Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C et al (2012) Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 65:934–939. https://doi.org/10.1016/j.jclinepi.2011.11.014
doi: 10.1016/j.jclinepi.2011.11.014
pubmed: 22742910
pmcid: 22742910
Liao X, Li G, McBride R, Houldsworth J, Harpaz N, Polydorides AD (2020) Clinicopathological and molecular characterisation of Crohn’s disease-associated small bowel adenocarcinomas. J Crohns Colitis 14:287–294. https://doi.org/10.1093/ecco-jcc/jjz135
doi: 10.1093/ecco-jcc/jjz135
pubmed: 31388669
Hussain T, Jeganathan NA, Karagkounis G, Stocchi L, Shawki S, Holubar SD et al (2020) Small bowel adenocarcinoma in Crohn’s disease: a rare but devastating complication. Tech Coloproctol 24:1055–1062. https://doi.org/10.1007/s10151-020-02269-8
doi: 10.1007/s10151-020-02269-8
pubmed: 32596760
Wieghard N, Mongoue-Tchokote S, Young JI, Sheppard BC, Tsikitis VL (2017) Prognosis of small bowel adenocarcinoma in Crohn’s disease compares favourably with de novo small bowel adenocarcinoma. Colorectal Dis 19:446–455. https://doi.org/10.1111/codi.13531
doi: 10.1111/codi.13531
pubmed: 27659145
Weber NK, Fletcher JG, Fidler JL, Barlow JM, Pruthi S, Loftus EV Jr et al (2015) Clinical characteristics and imaging features of small bowel adenocarcinomas in Crohn’s disease. Abdom Imaging 40:1060–1067. https://doi.org/10.1007/s00261-014-0144-7
doi: 10.1007/s00261-014-0144-7
pubmed: 24760323
Lashner BA (1992) Risk factors for small bowel cancer in Crohn’s disease. Dig Dis Sci 37:1179–1184. https://doi.org/10.1007/BF01296557
doi: 10.1007/BF01296557
pubmed: 1499440
Michelassi F, Testa G, Pomidor WJ, Lashner BA, Block GE (1993) Adenocarcinoma complicating Crohn’s disease. Dis Colon Rectum 36:654–661. https://doi.org/10.1007/BF02238592
doi: 10.1007/BF02238592
pubmed: 8348849
Widmar M, Greenstein AJ, Sachar DB, Harpaz N, Bauer JJ, Greenstein AJ (2011) Small bowel adenocarcinoma in Crohn’s disease. J Gastrointest Surg 15:797–802. https://doi.org/10.1007/s11605-011-1441-x
doi: 10.1007/s11605-011-1441-x
pubmed: 21336499
Fields AC, Hu FY, Lu P, Irani J, Bleday R, Goldberg JE et al (2020) Small bowel adenocarcinoma: is there a difference in survival for Crohn’s versus sporadic cases? J Crohns Colitis 14:303–308. https://doi.org/10.1093/ecco-jcc/jjz157
doi: 10.1093/ecco-jcc/jjz157
pubmed: 31541248
Bojesen RD, Riis LB, Hogdall E, Nielsen OH, Jess T (2017) Inflammatory bowel disease and small bowel cancer risk, clinical characteristics, and histopathology: a population-based study. Clin Gastroenterol Hepatol 15(1900–7)
Kaerlev L, Teglbjaerg PS, Sabroe S, Kolstad HA, Ahrens W, Eriksson M et al (2001) Medical risk factors for small-bowel adenocarcinoma with focus on Crohn disease: a European population-based case-control study. Scand J Gastroenterol 36:641–646. https://doi.org/10.1080/003655201750163150
doi: 10.1080/003655201750163150
pubmed: 11424324
Kvist N, Jacobsen O, Norgaard P, Ockelmann HH, Kvist HK, Schou G et al (1986) Malignancy in Crohn’s disease. Scand J Gastroenterol 21:82–86. https://doi.org/10.3109/00365528609034627
doi: 10.3109/00365528609034627
pubmed: 3952455
Simon M, Cosnes J, Gornet JM, Seksik P, Stefanescu C, Blain A et al (2017) Endoscopic detection of small bowel dysplasia and adenocarcinoma in Crohn’s disease: a prospective cohort-study in high-risk patients. J Crohns Colitis 11:47–52. https://doi.org/10.1093/ecco-jcc/jjw123
doi: 10.1093/ecco-jcc/jjw123
pubmed: 27405958
Grolleau C, Pote NM, Guedj NS, Zappa M, Theou-Anton N, Bouhnik Y et al (2017) Small bowel adenocarcinoma complicating Crohn’s disease: a single-centre experience emphasizing the importance of screening for dysplasia. Virchows Arch 471:611–617. https://doi.org/10.1007/s00428-017-2125-z
doi: 10.1007/s00428-017-2125-z
pubmed: 28421339
Elriz K, Carrat F, Carbonnel F, Marthey L, Bouvier AM, Beaugerie L et al (2013) Incidence, presentation, and prognosis of small bowel adenocarcinoma in patients with small bowel Crohn’s disease: a prospective observational study. Inflamm Bowel Dis 19:1823–1826. https://doi.org/10.1097/MIB.0b013e31828c84f2
doi: 10.1097/MIB.0b013e31828c84f2
pubmed: 23702807
Palascak-Juif V, Bouvier AM, Cosnes J, Flourie B, Bouche O, Cadiot G et al (2005) Small bowel adenocarcinoma in patients with Crohn’s disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis 11:828–832. https://doi.org/10.1097/01.mib.0000179211.03650.b6
doi: 10.1097/01.mib.0000179211.03650.b6
pubmed: 16116317
Soyer P, Hristova L, Boudghene F, Hoeffel C, Dray X, Laurent V et al (2012) Small bowel adenocarcinoma in Crohn disease: CT-enterography features with pathological correlation. Abdom Imaging 37:338–349. https://doi.org/10.1007/s00261-011-9772-3
doi: 10.1007/s00261-011-9772-3
pubmed: 21671043
Yamamoto T, Allan RN, Keighley MR (2001) Long-term outcome of surgical management for diffuse jejunoileal Crohn’s disease. Surgery 129:96–102. https://doi.org/10.1067/msy.2001.109497
doi: 10.1067/msy.2001.109497
pubmed: 11150039
Connell WR, Sheffield JP, Kamm MA, Ritchie JK, Hawley PR, Lennard-Jones JE (1994) Lower gastrointestinal malignancy in Crohn’s disease. Gut 35:347–352. https://doi.org/10.1136/gut.35.3.347
doi: 10.1136/gut.35.3.347
pubmed: 8150345
pmcid: 1374588
Lindgren A, Wallerstedt S, Olsson R (1996) Prevalence of Crohn’s disease and simultaneous occurrence of extraintestinal complications and cancer. An epidemiologic study in adults. Scand J Gastroenterol 31:74–8. https://doi.org/10.3109/00365529609031630
Giuffrida P, Arpa G, Grillo F, Klersy C, Sampietro G, Ardizzone S et al (2020) PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability. Mod Pathol 33:1398–1409. https://doi.org/10.1038/s41379-020-0497-0
doi: 10.1038/s41379-020-0497-0
pubmed: 32066859
Biancone L, Armuzzi A, Scribano ML, Castiglione F, D’Inca R, Orlando A et al (2020) Cancer risk in inflammatory bowel disease: a 6-year prospective multicenter nested case-control IG-IBD study. Inflamm Bowel Dis 26:450–459. https://doi.org/10.1093/ibd/izz155
doi: 10.1093/ibd/izz155
pubmed: 31498388
Katsanos KH, Christodoulou DK, Michael M, Ioachim E, Tsianos GV, Agnantis N et al (2005) Inflammatory bowel disease-related dysplasia and cancer: a referral center study in northwestern Greece. Eur J Intern Med 16:170–175. https://doi.org/10.1016/j.ejim.2004.09.016
doi: 10.1016/j.ejim.2004.09.016
pubmed: 15967331
Fireman Z, Grossman A, Lilos P, Hacohen D, Bar Meir S, Rozen P et al (1989) Intestinal cancer in patients with Crohn’s disease. A population study in central Israel. Scand J Gastroenterol 24:346–50. https://doi.org/10.3109/00365528909093058
Bernstein CN, Blanchard JF, Kliewer E, A Wajda (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91:854–862.
doi: 10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z
pubmed: 11241255
Algaba A, Guerra I, Marin-Jimenez I, Quintanilla E, Lopez-Serrano P, Garcia-Sanchez MC et al (2015) Incidence, management, and course of cancer in patients with inflammatory bowel disease. J Crohns Colitis 9:326–333. https://doi.org/10.1093/ecco-jcc/jjv032
doi: 10.1093/ecco-jcc/jjv032
pubmed: 25687203
Kamiya T, Ando T, Ishiguro K, Maeda O, Watanabe O, Hibi S et al (2012) Intestinal cancers occurring in patients with Crohn’s disease. J Gastroenterol Hepatol 27(Suppl 3):103–107. https://doi.org/10.1111/j.1440-1746.2012.07082.x
doi: 10.1111/j.1440-1746.2012.07082.x
pubmed: 22486881
Jung YS, Han M, Park S, Kim WH, Cheon JH (2017) Cancer risk in the early stages of inflammatory bowel disease in Korean patients: a nationwide population-based study. J Crohns Colitis 11:954–962. https://doi.org/10.1093/ecco-jcc/jjx040
doi: 10.1093/ecco-jcc/jjx040
pubmed: 28333358
Chin YH, Ng CH, Lin SY, Jain SR, Kong G, Koh JWH et al (2021) Systematic review with meta-analysis: the prevalence, risk factors and outcomes of upper gastrointestinal tract. Crohn’s disease Dig Liver Dis. https://doi.org/10.1016/j.dld.2021.07.037
Farmer RG, Whelan G, Fazio VW (1985) Long-term follow-up of patients with Crohn’s disease: relationship between the clinical pattern and prognosis. Gastroenterology 88:1818–1825. https://doi.org/10.1016/0016-5085(85)90006-X
doi: 10.1016/0016-5085(85)90006-X
pubmed: 3922845
Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot J-F, Peyrin-Biroulet L, Danese S (2019) Comorbidities in inflammatory bowel disease: a call for action. The Lancet Gastroenterology & Hepatology 4:643–654. https://doi.org/10.1016/S2468-1253(19)30173-6
doi: 10.1016/S2468-1253(19)30173-6
Bhamre R, Sawrav S, Adarkar S, Sakaria R, J Bhatia S (2018) Psychiatric comorbidities in patients with inflammatory bowel disease. Indian J Gastroenterol 37:307–312. https://doi.org/10.1007/s12664-018-0870-9
doi: 10.1007/s12664-018-0870-9
pubmed: 30196516
Buckley JA, Siegelman SS, Jones B, Fishman EK (1997) The accuracy of CT staging of small bowel adenocarcinoma: CT/pathologic correlation. J Comput Assist Tomogr 21:986–991. https://doi.org/10.1097/00004728-199711000-00025
doi: 10.1097/00004728-199711000-00025
pubmed: 9386295
Martineau C, Lefèvre JH, Chafai N, O’Connell L, Svrcek M, Beaugerie L et al (2021) Intraoperative random biopsies of strictureplasty sites can detect early small-bowel adenocarcinoma in patients with Crohn’s disease. Dig Liver Dis 53:924–926. https://doi.org/10.1016/j.dld.2021.04.017
doi: 10.1016/j.dld.2021.04.017
pubmed: 33994124
Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G et al (2018) ECCO-ESCP consensus on surgery for Crohn’s disease. Journal of Crohn’s and Colitis 12:1–16. https://doi.org/10.1093/ecco-jcc/jjx061
doi: 10.1093/ecco-jcc/jjx061
pubmed: 28498901
Partridge SK, Hodin RA (2004) Small bowel adenocarcinoma at a strictureplasty site in a patient with Crohn’s disease: report of a case. Dis Colon Rectum 47:778–781. https://doi.org/10.1007/s10350-003-0101-y
doi: 10.1007/s10350-003-0101-y
pubmed: 15037927
Axelrad JE, Lichtiger S, Yajnik V (2016) Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol 22:4794–4801. https://doi.org/10.3748/wjg.v22.i20.4794
doi: 10.3748/wjg.v22.i20.4794
pubmed: 27239106
pmcid: 4873872
Vanoli A, Di Sabatino A, Martino M, Klersy C, Grillo F, Mescoli C et al (2017) Small bowel carcinomas in celiac or Crohn’s disease: distinctive histophenotypic, molecular and histogenetic patterns. Mod Pathol 30:1453–1466. https://doi.org/10.1038/modpathol.2017.40
doi: 10.1038/modpathol.2017.40
pubmed: 28664941
Hong SH, Koh YH, Rho SY, Byun JH, Oh ST, Im KW et al (2009) Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol 39:54–61. https://doi.org/10.1093/jjco/hyn122
doi: 10.1093/jjco/hyn122
pubmed: 18997182
Sakae H, Kanzaki H, Nasu J, Akimoto Y, Matsueda K, Yoshioka M et al (2017) The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study. Br J Cancer 117:1607–1613. https://doi.org/10.1038/bjc.2017.338
doi: 10.1038/bjc.2017.338
pubmed: 28982111
pmcid: 5729438
Wu TJ, Yeh CN, Chao TC, Jan YY, Chen MF (2006) Prognostic factors of primary small bowel adenocarcinoma: univariate and multivariate analysis. World J Surg 30:391–8; discussion 9. https://doi.org/10.1007/s00268-005-7898-6
Strong S, Steele SR, Boutrous M, Bordineau L, Chun J, Stewart DB et al (2015) Clinical practice guideline for the surgical management of Crohn’s disease. Dis Colon Rectum 58:1021–1036. https://doi.org/10.1097/DCR.0000000000000450
doi: 10.1097/DCR.0000000000000450
pubmed: 26445174
Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ et al (2017) Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol 3:1546–1553. https://doi.org/10.1001/jamaoncol.2017.1051
doi: 10.1001/jamaoncol.2017.1051
pubmed: 28617917
pmcid: 5710195
Jun SY, Lee EJ, Kim MJ, Chun SM, Bae YK, Hong SU et al (2017) Lynch syndrome-related small intestinal adenocarcinomas Oncotarget 2017(8):21483–21500. https://doi.org/10.18632/oncotarget.15277
doi: 10.18632/oncotarget.15277
Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X (2019) Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 18:26. https://doi.org/10.1186/s12943-019-0954-x
doi: 10.1186/s12943-019-0954-x
pubmed: 30782187
pmcid: 6379961
Caputo F, Santini C, Bardasi C, Cerma K, Casadei-Gardini A, Spallanzani A et al (2019) BRAF-mutated colorectal cancer: clinical and molecular insights. Int J Mol Sci 2019:20. https://doi.org/10.3390/ijms20215369
doi: 10.3390/ijms20215369
Wheeler JM, Warren BF, Mortensen NJ, Kim HC, Biddolph SC, Elia G et al (2002) An insight into the genetic pathway of adenocarcinoma of the small intestine. Gut 50:218–223. https://doi.org/10.1136/gut.50.2.218
doi: 10.1136/gut.50.2.218
pubmed: 11788563
pmcid: 1773117
Arai M, Shimizu S, Imai Y, Nakatsuru Y, Oda H, Oohara T et al (1997) Mutations of the Ki-ras, p53 and APC genes in adenocarcinomas of the human small intestine. Int J Cancer 70:390–395.
doi: 10.1002/(sici)1097-0215(19970207)70:4<390::aid-ijc3>3.0.co;2-r
pubmed: 9033644
Breuhahn K, Singh S, Schirmacher P, Blaker H (2008) Large-scale N-terminal deletions but not point mutations stabilize beta-catenin in small bowel carcinomas, suggesting divergent molecular pathways of small and large intestinal carcinogenesis. J Pathol 215:300–307. https://doi.org/10.1002/path.2362
doi: 10.1002/path.2362
pubmed: 18491352
Mogire RM, Mutua A, Kimita W, Kamau A, Bejon P, Pettifor JM et al (2020) Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis. Lancet Glob Health 8:e134–e142. https://doi.org/10.1016/S2214-109X(19)30457-7
doi: 10.1016/S2214-109X(19)30457-7
pubmed: 31786117
Noubiap JJ, Nansseu JR, Nyaga UF, Nkeck JR, Endomba FT, Kaze AD et al (2019) Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health 7:e448–e60. https://doi.org/10.1016/S2214-109X(18)30487-X
Rucker G, Schwarzer G, Carpenter JR, Schumacher M (2008) Undue reliance on I
doi: 10.1186/1471-2288-8-79
pubmed: 19036172
pmcid: 2648991
Borges Migliavaca C, Stein C, Colpani V, Barker TH, Munn Z, Falavigna M et al (2020) How are systematic reviews of prevalence conducted? A methodological study. BMC Med Res Methodol 20:96. https://doi.org/10.1186/s12874-020-00975-3
doi: 10.1186/s12874-020-00975-3
pubmed: 32336279
pmcid: 7184711